Caris Life Sciences (CAI) Preferred Dividend Payments (2024 - 2025)

Caris Life Sciences (CAI) posted quarterly Preferred Dividend Payments of $61.0 million for Q2 2025, up 149.25% quarter-over-quarter from $24.5 million in Q1 2025.

Caris Life Sciences (CAI) Preferred Dividend Payments (2024 - 2025) Analysis & Trends

Caris Life Sciences' Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $61.0 million for Q2 2025.

  • In Q2 2025, Preferred Dividend Payments changed N/A year-over-year to $61.0 million; the TTM figure through Mar 2026 stood at $61.0 million (down 49.54% YoY), while the FY2025 annual figure was $85.4 million, down 11.35% from the prior year.
  • Preferred Dividend Payments for Q2 2025 stood at $61.0 million, up from $24.5 million in the prior quarter.
  • The five-year high for Preferred Dividend Payments was $96.4 million in Q4 2024, with the low at $24.5 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Pref Dividends (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Caris Life Sciences 6.16 Bn 5.37 Bn 182.38 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2025 60.97 Mn
Mar 31, 2025 24.46 Mn
Dec 31, 2024 96.37 Mn